Industry Briefs: November 5, 2012 - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Industry Briefs: November 5, 2012
A roundup of additional company and people news from pharmaceutical and biopharmaceutical companies, their suppliers, and contract-service providers.


Company News

Agere Pharmaceuticals has expanded its cGMP spray-dry capabilities. Read More

Charles River has agreed to acquire a majority ownership of Vital River. Read More

Cytovance Biologics has been awarded a biopharmaceutical development and manufacturing contract by Fountain BioPharma. Read More

Eli Lilly has announced a $140-million expansion to the company’s Indianapolis insulin manufacturing operations. Read More

Integrated Project Services has opened a new office São Paulo, Brazil. Read More

Pharmalink has entered into a contract with Patheon for the manufacturing of Nefecon, for treating the underlying pathology of progressive IgA nephropathy, the most common form of primary glomerulonephritis and a leading cause of end-stage renal disease.

Wacker Biotech and XL-protein have agreed to produce PASylated biopharmaceuticals. Read More

People News

Astellas has named Jeffrey Bloss vice-president of scientific and medical affairs. Read More

Cedarburg Hauser Pharmaceuticals has appointed John K. Lynch as chief scientific officer. Read More

Patheon has appointed Michael Lehmann as head of global pharmaceutical development services. Read More

Teva has announced several changes to its executive leadership team. Allan Oberman has been named president and CEO of Teva Americas Generics, and Jill DeSimone has been appointed as senior vice-president and general manager of Teva Global Women’s Health. William S. Marth will retire as president and CEO of Teva Americas. Read More

Following its acquisition of Actavis, Watson has announced a new global generics management team, including Siggi Olafsson, as president of the division, and several other appointments. Read More

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
27%
Oversee medical treatment of patients in the US.
12%
Provide treatment for patients globally.
8%
All of the above.
46%
No government involvement in patient treatment or drug development.
7%
Jim Miller Outsourcing Outlook Jim MillerCMO Industry Thins Out
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerFluorination Remains Key Challenge in API Synthesis
Marilyn E. Morris Guest EditorialMarilyn E. MorrisBolstering Graduate Education and Research Programs
Jill Wechsler Regulatory Watch Jill Wechsler Biopharma Manufacturers Respond to Ebola Crisis
Sean Milmo European Regulatory WatchSean MilmoHarmonizing Marketing Approval of Generic Drugs in Europe
Seven Steps to Solving Tabletting and Tooling ProblemsStep 1: Clean
Legislators Urge Added Incentives for Ebola Drug Development
FDA Reorganization to Promote Drug Quality
FDA Readies Quality Metrics Measures
New FDA Team to Spur Modern Drug Manufacturing

Click here